An elderly woman with weight loss and diarrhoea by Mitchell AL & Pearce SHS
Newcastle University e-prints  
Date deposited:  7th May 2010 
Version of file:  Author final 
Peer Review Status: Peer Reviewed 
Citation for published item: 
Mitchell AL, Pearce SHS. An elderly woman with weight loss and diarrhoea. British Medical Journal 
2009,338 b1721. 
Further information on publisher website: 
http://group.bmj.com/ 
Publishers copyright statement: 
This article was originally published by BMJ publishing, 2009 and can be seen (with access permissions) 
from the link below: 
http://www.bmj.com/ 
Always use the definitive version when citing.  
Use Policy: 
The full-text may be used and/or reproduced and given to third parties in any format or medium, 
without prior permission or charge, for personal research or study, educational, or not for profit 
purposes provided that: 
• A full bibliographic reference is made to the original source 
• A link is made to the metadata record in Newcastle E-prints 
• The full text is not changed in any way. 
The full-text must not be sold in any format or medium without the formal permission of the 
copyright holders. 
 
 
 
Robinson Library, University of Newcastle upon Tyne,  Newcastle upon Tyne. NE1 
7RU.  Tel. 0191 222 6000 
Endgames 
Endocrinology ~ An elderly lady with weight loss and diarrhoea 
Dr Anna L Mitchell, Academic Clinical Fellow   
Professor Simon Pearce, Professor of Endocrinology 
The University of Newcastle upon Tyne, Institute of Human Genetics, Central 
Parkway, Newcastle upon Tyne, NE1 3BZ 
Corresponding author email address: annamitchell@doctors.org.uk 
Case History 
An 80 year old lady presented in July 2006 with a 2 month history of 
diarrhoea.  She complained of passing loose stools approximately 4 times a 
day, and having to get up at night to open her bowels.  She had noticed that 
her appetite had been poor and as a consequence, thought that she had lost 
approximately one stone in weight.  She had noticed that the diarrhoea began 
shortly after one of her regular medications, dothiepin, had been stopped by 
her GP.  Her only past medical history was hypertension, angina and a benign 
breast lump.  She was a non-smoker and did not drink any alcohol.  Her 
regular medications were as follows: aspirin 75mg OD, atenolol 50mg BD,  
bendroflumethiazide 2.5mg OD, doxazosin 6mg OD and simvastatin 40mg 
OD.   
An outpatient CT colonography was arranged by a gastroenterologist and was 
reported as normal.   
Routine blood tests were requested at the initial consultation and the results 
were as follows (normal ranges and units shown in brackets): 
Hb 13.1 (13.0 – 18.0 g/dl) 
Plt 150 (150 – 450 x 10
9
/L) 
WCC 5.4 (4 – 11 x 109/L) 
Na 139 (135 – 145 mmol/L) 
K 3.8 (3.4 – 5.0 mmol/L) 
Ur 6.9 (3.1 – 7.9mmol/L) 
Cr 105 (70 – 110 mmol/L) 
Adjusted Ca 2.32 mmol/L 
Bilirubin 13 (0 – 19 µmol/L ) 
Alk phos 60 (35 – 120 U/L) 
ALT 24 (0 – 45 U/L ) 
TSH <0.05 (0.3-4.7 mIU/L) 
Free thyroxine 19 (11-23 pmol/L) 
Free T3 6.6 (3.5-6.5 pmol/L) 
Thyroid peroxidise antibody 39 (0 – 
60 kU/L)
Her thyroid function was subsequently monitored (table 1).   
Table 1: thyroid function test results from July 2006 to October 2007 (normal 
ranges shown in brackets, abnormal results are shown in bold) 
 July 
2006 
Sept 
2006
Nov 
2006 
Oct 
2007 
TSH (0.3-4.7) <0.05 <0.05 <0.05 <0.05
FT4 (11-23) 19 18 19 23 
FT3 (3.5-6.5) 6.6 6.7 6.5 6.9
.
Questions 
1. What is the biochemical abnormality at initial presentation?  
2. What do the subsequent thyroid function tests show?  
3. What are the potential causes of a suppressed TSH with normal T4 
and T3?  
4. What are the risks associated with this biochemical pattern?   
5. What treatment would you offer this lady?  
Answers 
Short answers 
1. This lady has presented with mild T3 thyrotoxicosis (TSH suppressed, 
FT4 normal, FT3 raised just above the upper limit of normal).   
2. At subsequent follow up appointments, her thyroid function varies from 
T3 thyrotoxicosis (T3T) to subclinical hyperthyroidism (SH).  
3. T3T is almost always due to endogenous hyperthyroidism, whereas 
potential causes of SH may be endogenous or exogenous and include: 
Endogenous causes (T3T or SH): 
• Graves’ disease 
• Autonomously functioning thyroid adenoma 
• Multinodular goitre 
Exogenous causes (SH only): 
• Excessive thyroid hormone replacement therapy in hypothyroid 
individuals 
• Intentional thyroid hormone suppressive therapy for differentiated 
thyroid carcinoma or nodular thyroid disease 
• Iatrogenic e.g. Drugs (glucocorticoids, opiates, levodopa, 
amiodarone) and IV contrast agents containing iodine 
• Pregnancy (due to placental hCG stimulation of the thyroid) 
• Non-thyroidal illness (sick euthyroid syndrome) 
4. The associated risks of T3T and SH include:  
• Atrial fibrillation and stroke disease 
• Cardiovascular disease 
• Dementia 
• Fracture 
• Premature death 
5. T3T can be regarded as the earliest or mildest form of overt 
hyperthyroidism and should generally be treated in the same way as full-
blown thyrotoxicosis. Treatment options for SH include: 
• Monitoring only 
• Beta blockers 
• Antithyroid drugs e.g. carbimazole 
• Radioactive iodine 
Long answers 
While T3T may be symptomatic, SH is often a laboratory diagnosis, 
characterised by the biochemical findings of low or undetectable serum 
thyroid stimulating hormone (TSH) level with normal levels of thyroxine (T4) 
and tri-iodothyronine (T3), and little in the way of symptoms. 
Both T3T and SH may result from endogenous overproduction of thyroid 
hormones (e.g. Graves’ disease, an autonomously functioning thyroid 
adenoma, toxic multinodular goitre). However, SH may also be owing to 
intentional or unintentional over-administration of thyroid hormones.  This 
biochemical picture is also seen in normal pregnancy [1], in sick euthyroid 
syndrome[2] and in patients taking glucocorticoids[3] amiodarone[4], levodopa [5],
opiates[6], and following injection of IV contrast agents containing iodine[7].
T3T and SH are more common in women than in men (female:male = 1.5:1).  
T3T is uncommon, but SH affects between 1 and 2% of women over the age 
of 60[8, 9], and up to 3% of people over 80 years of age[10].   
SH was once considered a benign biochemical abnormality.  However, in 
recent years, evidence has accrued which demonstrates that persistent SH is 
associated with significant morbidity and mortality due to cardiovascular and 
cerebrovascular disease.  In a study of community-dwelling over 60 year olds, 
at the 5 year follow-up point, the circulatory mortality in study participants with 
a TSH <0.5 was 25% compared with 15% in participants with a TSH within 
normal limits.  This represents a 10% fall in survival in those with SH 
compared to those with normal thyroid function[11].  This finding has been 
replicated across a cohort of the “oldest old” in the Leiden 85-Plus Study [12].
SH may progress to T3T or full-blown overt hyperthyroidism with its 
associated symptoms; the incidence of progression to overt thyrotoxicosis 
being approximately 5% per year[13, 14].  In addition, the risk of atrial fibrillation 
(AF), a long established risk factor for cerebrovascular disease, is increased 3 
fold in patients with SH[15]. AF risk in one study was little different between SH 
and overt thyrotoxicosis
[16]
. SH has also been demonstrated to be associated 
with dementia.  In one population-based study, the risk of dementia or 
Alzheimer’s disease was increased more than 3 fold in participants with a low 
TSH[17].  Finally, just as overt hyperthyroidism is a risk factor for reduced bone 
mineral density and fracture, so is SH.  A prospective cohort study clearly 
demonstrated that women over 65 years of age with low serum TSH levels 
have a 3 fold increased risk of sustaining a new hip fracture and a 4 fold 
increased risk of sustaining a new vertebral fracture compared with women 
with normal TSH levels[18].   
In terms of treatment options, both antithyroid drugs and radioactive iodine 
are effective at correcting the biochemical abnormalities of SH, however there 
is no robust evidence to suggest that these treatments lead to a reduction in 
the associated morbidity and mortality, or an improvement in quality of life and 
survival.  In addition, these treatments have their own drawbacks.  For 
example, carbimazole, one of the most commonly used of the antithyroid 
drugs, is rarely associated with agranulocytosis which has a mortality of 10% 
in the elderly[19].  In addition, patients with SH are often older and therefore 
taking multiple medications.  Adding further medications can result in 
confusion, compliance problems and increases the chances of drug 
interactions.  In contrast, radioiodine therapy is a convenient one-off treatment 
however it may render the recipient hypothyroid and therefore dependent 
upon thyroid replacement therapy for life, again increasing the patient’s tablet 
burden.  Attempts to establish an evidence base for the treatment of SH 
through randomised clinical trials have proved difficult thus far.   
Despite the lack of evidence, many endocrinologists do treat patients with SH.  
A recent survey of American thyroid specialists showed that most favoured 
treating older patients actively, with 66% opting to treat an older woman with 
SH[20]. A similar survey of UK endocrinologists showed a more conservative 
approach, with one third of those who responded stating that they would 
generally treat the patient, particularly if they were in atrial fibrillation or had 
osteoporosis.  Of those offering treatment for SH, 63%, 35%, 1% and 0·4% 
would recommend radioiodine, thionamide, beta-blocker and thyroidectomy, 
respectively[21].  Given this uncertainty, options for treatment should be 
discussed with the patient and the pros and cons of each option explored.   
Outcome of the Case 
This lady was investigated by the gastroenterologists and no sinister cause for 
her diarrhoea was found.  Dothiepin was restarted, the diarrhoea improved 
and her weight increased.  The gastroenterologists discharged her from their 
care, after referring her to the endocrine department for investigation of her 
abnormal thyroid function tests.  She was investigated and found to have a 
solitary toxic thyroid nodule (figure 1).  She felt well in herself and therefore 
declined the offer of radioactive iodine therapy and opted for careful 
monitoring.   
Figure 1: Image from this patient’s thyroid 99Tc Pertechnetate scan illustrating 
a “hot spot” corresponding to a solitary toxic thyroid nodule.   
Unfortunately, in October 2007, the patient began to feel very short of breath 
and complained of palpitations and dizzy spells.  A 12-lead ECG showed AF 
and her thyroid function tests demonstrated worsening T3T (TSH <0.05, FT4 
23, FT3 6.9).  She was given digoxin for rate control and was anticoagulated 
with warfarin.  She agreed to radioactive iodine therapy and received this in 
November 2007.   
In January 2008 she was clinically euthyroid however her TSH was 
increasing, therefore she was commenced on a low dose of thyroxine (25 
micrograms per day) in anticipation of her becoming hypothyroid.  She 
remained in AF and so was referred for DC cardioversion.  In April 2008 she 
was successfully cardioverted back into sinus rhythm with significant 
improvement in her symptoms.  Immediately after cardioversion, her digoxin 
was stopped and her atenolol dose was reduced to 50mg once daily.  She 
continued with warfarin for a further 6 months after cardioversion, and having 
confirmed that she remained in sinus rhythm, this was stopped in June 2008.  
She is currently well, remains in sinus rhythm and is maintained on 25 
micrograms of thyroxine daily.   
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